trending Market Intelligence /marketintelligence/en/news-insights/trending/-1ozLo8mdraXZd_-qR8NxA2 content esgSubNav
In This List

ThromboGenics shareholders approve name change

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


ThromboGenics shareholders approve name change

Belgium-based biotechnology company ThromboGenics NV gained shareholders approval to change its name to Oxurion NV at an extraordinary general meeting held Sept. 3.

ThromboGenics' lead product JETREA is used to treat declining visual function due to vitreomacular traction syndrome.

The company's ticker on Euronext Brussels will change to OXUR from THR.

ThromboGenics said in a statement that it will also change its corporate website in connection with the name change.